Work

1621MO Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update

Year: 2020

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.1847

Authors: R.L. Jones, C. Serrano, M. von Mehren, S. George, M. Heinrich, Y-K. Kang, P. Schoeffski, P. Cassier, O. Mir, S.P. Chawla, F.A. Eskens, P. Rutkowski, W.D. Tap, T. Zhou, M. Roche, S. Bauer

Institutions: Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Vall d'Hebron Institute of Oncology, Fox Chase Cancer Center, Dana-Farber Cancer Institute, Oregon Health & Science University, OHSU Knight Cancer Institute, Asan Medical Center, University of Ulsan, Universitair Ziekenhuis Leuven, Centre Léon Bérard, Institut Gustave Roussy, Sarcoma Oncology Center, Erasmus MC Cancer Institute, The Maria Sklodowska-Curie National Research Institute of Oncology, Memorial Sloan Kettering Cancer Center, Blueprint Medicines (United States), Essen University Hospital, Stiftung Universitätsmedizin Essen

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3087845135

FWCI: 0.551

Cites:

Cited by: 3

Related to: 10